Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC
Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC
Active, not recruiting · NCT04413123 · Registry updated 2026-07-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, MIT family translocation renal cell carcinoma, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, neoplasm, papillary renal cell carcinoma, renal cell carcinoma, urinary system disorder | Active, not recruiting | Phase 2 | 2026-07-23 | NCT04413123 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Bradley A. McGregor, MD | 1 |
| Bristol-Myers Squibb | 422 |
| Exelixis | 77 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beth Israel Deaconess Medical Center | Boston | United States | 45 |
| Brigham & Woman's Hospital | Boston | United States | 2 |
| Dana Farber Cancer Institute | Boston | United States | 133 |
| UT Southwestern Medical | Dallas | United States | 1 |